Eradication of Ventricular Assist Device Driveline Infection in Paediatric Patients with Taurolidine

Johannes Weichsel, Benito Baldauf, Hendrik Bonnemeier, Ernest W Lau, Sven Dittrich, Robert Cesnjevar, Johannes Weichsel, Benito Baldauf, Hendrik Bonnemeier, Ernest W Lau, Sven Dittrich, Robert Cesnjevar

Abstract

Ventricular assist devices (VADs) are used to provide mechanical circulatory support to patients with end-stage heart failure. The driveline connecting the external power source to the pump(s) of the intra-corporal VAD breaches the protective skin barrier and provides a track for microbes to invade the interior of the patient's body. Driveline infection constitutes a major and potentially fatal vulnerability of VAD therapy. Driveline infection cannot traditionally be salvaged and requires the extraction of the entire VAD system. We report here the successful eradication of a VAD driveline infection with a taurolidine-containing antimicrobial solution used for preventing the infection of cardiac implantable electronic devices. If replicated in more cases, the novel treatment concept described here may provide a valuable alternative management strategy of salvage rather than explantation for VAD driveline infection.

Keywords: driveline; infection; left ventricular assist device; taurolidine.

Conflict of interest statement

B. Baldauf is a medical consultant for the manufacturer of TauroPace™. The other authors declare no conflict of interest in relation to this publication.

Figures

Figure 1
Figure 1
Typical appearance of petechial hemorrhages in the skin around the exit site in VAD driveline infection.

References

    1. Kormos R.L., Cowger J., Pagani F.D., Teuteberg J.J., Goldstein D.J., Jacobs J.P., Higgins R.S., Stevenson L.W., Stehlik J., Atluri P., et al. The Society of Thoracic Surgeons Intermacs database annual report: Evolving indications, outcomes, and scientific partnerships. J. Heart Lung Transplant. 2019;38:114–126. doi: 10.1016/j.healun.2018.11.013.
    1. Kirklin J.K., Pagani F.D., Kormos R.L., Stevenson L.W., Blume E.D., Myers S.L., Miller M.A., Baldwin J.T., Young J.B., Naftel D.C. Eighth annual INTERMACS report: Special focus on framing the impact of adverse events. J. Heart Lung Transplant. 2017;36:1080–1086. doi: 10.1016/j.healun.2017.07.005.
    1. Brückner W.L. Taurolin: E. neues Konzept zur Antimikrobiellen Chemotherapie Chirurg. Infektionen; Dieser Bd. enth. d. Anlässl. d. Internat. Taurolin-Symposiums am 22. Oktober 1983 in München Gehaltenen Vorträge in Überarb. u. erw. Form. Urban & Schwarzenberg; Vienna, Austria: Munich, Germany: Amsterdam, The Netherlands: 1985.
    1. Goulet O., Breton A., Coste M.E., Dubern B., Ecochard-Dugelay E., Guimber D., Loras-Duclaux I., Abi Nader E., Marinier E., Peretti N., et al. Pediatric Home Parenteral Nutrition in France: A six years national survey. Clin. Nutr. 2021;40:5278–5287. doi: 10.1016/j.clnu.2021.08.002.
    1. Zeriouh M., Sabashnikov A., Patil N.P., Schmack B., Zych B., Mohite P.N., Garcia Saez D., Koch A., Mansur A., Soresi S., et al. Use of taurolidine in lung transplantation for cystic fibrosis and impact on bacterial colonization. Eur. J. Cardio-Thorac Surg. 2017;53:603–609. doi: 10.1093/ejcts/ezx359.
    1. Whale C.I., McMorrow J., Higton A., Fernandez N., Lawrence S., Jary C., Chambers D., Gabbay E., Musk M. Pleural Cavity Irrigation with Taurolidine during Lung Transplant May Reduce the Risk of Post−Operative Pleural Infection. Am. J. Respir. Crit. Care. Med. 2009;179:A4611. doi: 10.1164/ajrccm-conference.2009.179.1_MeetingAbstracts.A4611.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir